Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 25;17(8):e13186.
doi: 10.1111/irv.13186. eCollection 2023 Aug.

Infection-induced seroconversion and seroprevalence of SARS-CoV-2 among a cohort of children and youth in Montreal, Canada

Kate Zinszer  1   2 , Katia Charland  2 , Laura Pierce  2 , Adrien Saucier  1   2 , Marie-Ève Hamelin  3 , Margot Barbosa Da Torre  1   2 , Julie Carbonneau  3 , Cat Tuong Nguyen  4 , Gaston De Serres  5 , Jesse Papenburg  6 , Guy Boivin  3 , Caroline Quach  1   7
Affiliations

Infection-induced seroconversion and seroprevalence of SARS-CoV-2 among a cohort of children and youth in Montreal, Canada

Kate Zinszer et al. Influenza Other Respir Viruses. .

Abstract

The EnCORE study is a prospective serology study of SARS-CoV-2 in a cohort of children from Montreal, Canada. Based on data from our fourth round of data collection (May-October 2022), we estimated SARS-CoV-2 seroprevalence and seroconversion. Using multivariable regression, we identified factors associated with seroconversion. Our results show that previously seronegative children were approximately 9-12 times more likely to seroconvert during the early Omicron-dominant period compared to pre-Omicron rounds. Unlike the pre-Omicron rounds, the adjusted rate of seroconversion among 2- to 4-year-olds was higher than older age groups. As seen previously, higher seroconversion rates were associated with ethnic/racial minority status.

Keywords: Canada; SARS‐CoV‐2; adolescents; children; seroconversion; seroprevalence.

PubMed Disclaimer

Conflict of interest statement

JP reports grants from MedImmune, grants and personal fees from Merck and AbbVie, and personal fees from AstraZeneca, all outside the submitted work.

Figures

FIGURE 1
FIGURE 1
EnCORE cohort seroconversion rate per 100 person‐years (P‐Y) (light grey), percentage of Encore sample vaccinated with at least one dose, by age group (blues) and the Bank of Canada stringency index (%) for Quebec (dark grey) through Rounds 2, 3 and 4, with Omicron dominance starting in mid‐December 2021.
See this image and copyright information in PMC

References

    1. World Health Organization . One year since the emergence of COVID‐19 virus variant Omicron: what has changed, and why there hasn't been a new variant of concern. 2022. [cited 2022 Nov 25]. https://www.who.int/news-room/feature-stories/detail/one-year-since-the-...
    1. Centers for Disease Control and Prevention . COVID Data Tracker [Internet]. 2020. [cited 2022 Mar 28]. https://covid.cdc.gov/covid-data-tracker
    1. Zinszer K, McKinnon B, Bourque N, et al. Seroprevalence of anti‐SARS‐CoV‐2 antibodies among school and daycare children and personnel: protocol for a cohort study in Montreal, Canada. BMJ Open. 2021;11(7):e053245. doi: 10.1136/bmjopen-2021-053245 - DOI - PMC - PubMed
    1. Zinszer K, McKinnon B, Bourque N, et al. Seroprevalence of SARS‐CoV‐2 antibodies among children in school and day Care in Montreal, Canada. JAMA Netw Open. 2021;4(11):e2135975‐e. doi: 10.1001/jamanetworkopen.2021.35975 - DOI - PMC - PubMed
    1. Zinszer K, Charland K, Pierce L, et al. Pre‐Omicron seroprevalence, seroconversion, and seroreversion of infection‐induced SARS‐CoV‐2 antibodies among a cohort of children and teenagers in Montréal, Canada. Int J Infect Dis. 2023;131:119‐126. doi: 10.1016/j.ijid.2023.03.036 - DOI - PMC - PubMed

Publication types